Pharmacokinetics and pharmacodynamics study of mycophenolic acid in pediatric patients with glomerular diseases

PK/PD study and individualized therapeutic strategy of mycophenolic acid in pediatric nephrotic syndrome

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025533

Enrollment

Unknown

Registered

2019-08-31

Start date

2019-09-01

Completion date

Unknown

Last updated

2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glomerular diseases

Interventions

Case Series:mycophenolic acid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with glomerular diseases younger than 18 years old, and stabilized on the same dose of mycophenolic acid for >= 7 days.

Exclusion criteria

Exclusion criteria: Patients co-administered with immunosuppressive drugs except glucocorticoids or co-administered medicines that might affect mycophenolic acid concentrations; Patients with serious infections or multiple organ injuries.

Design outcomes

Primary

Measure	Time frame
pharmacokinetics;pharmacodynamics;	—

Countries

China

Contacts

Public ContactLuo Fang

Children's Hospital, Zhejiang University School of Medicine

fangluo@zju.edu.cn+86 571-86670401

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026